News
Thrombotech raised $1.4 million to finance Phase IIa trial
The company is planning Phase II clinical trials in Israel, Europe, and India.
12 January 2012, Tomer Kornfeld
Press to read article
Clal Biotech unit Thrombotech recruits patients for stroke study
The trial will be held in seven medical centers in Europe, India and in Israel
3 July 2011, Guy Katsovitch
Press to read article
Thrombotech Ltd., a Portfolio Company of Clal Biotechnology Industries Ltd. and Hadasit Bio-Holdings Ltd.,
Announces
Additional Clinical Progress
Thrombotech began patient enrollment in its Phase IIa ischemic stroke clinical trial
Press to read article
Thrombotech to begin Phase I trial of stroke treatment
Thrombotech Ltd. has obtained Ministry of Health approval to begin a Phase I human clinical trial of its stroke treatment.
4 February, 2010
Press to read article
Thrombotech reports positive stroke drug results
Portfolio company Thrombotech Ltd. reports positive results in the Phase I clinical trial of THR-18
7 September, 2010
Press to read article
 |
Thrombotech exhibited at the ILSI-Biomed 2009, hosted by the Israel Life Sciences Industry (ILSI), which
took place on June 15-17 in Tel Aviv, Israel. Thrombotech’s advances in stroke treatment were also promoted by Hadassit at the the Bio International Convention on May 18-21, 2009 in Atlanta, Georgia. |
Press coverage
Patience pays in biotech
Hadasit Bio Holdings allows investors access to early stage research.
Laura Goldman, Globes, 7 Oct 2008
http://www.globes.co.il/serveen/globes/docview.asp?did=1000388562&fid=980
Clal Biotechnology is strategic investor in Thrombotech CBI will invest $50,000 in Thrombotech’s blood clot treatment.
Gali Weinreb, Globes, 8
http://www.globes.co.il/serveen/globes/docview.asp?did=1000170767
Thrombotech to begin clinical trial of blood clot treatment
The company claims that its peptide can achieve its target as a stand alone drug without the need to be combined with existing drugs
on the market.
Batya Feldman, Globes, 19 Oct 2006
http://www.globes.co.il/serveen/globes/docview.asp?did=1000143727
Press releases
Lifesaving Treatment for Stroke Victims Developed by Thrombotech Ltd. : Hadassah-UPenn Team
Oct. 17, 2006
A Hadassah-University of Pennsylvania research team has developed a peptide that could save the lives and improve the treatment of
people stricken with ischemic strokes. Their findings, published recently in the prestigious medical journal, Nature Neuroscience,
indicate they have found a way to bypass the serious side effects of the thrombolytic agent tPA (a medication that dissolves clotting).
Currently, only about three percent of stroke victims can receive tPA, the only FDA-approved treatment for acute ischemic stroke,
because of the high incidence of post-treatment complications and the three-hour window when it is effective.
http://www.hbl.co.il/press_item.asp?ID=20
Hadasit Bio-Holdings Invests another NIS 700,000 in Thrombotech, One of its Portfolio Companies
Jun. 15, 2006
Hadasit Bio-Holdings Ltd. (Tel Aviv Stock Exchange symbol: HDST) announced today that it is continuing to apply the proceeds of its
public offering (January 2006) to investments in its subsidiaries and has invested approximately NIS 700,000
in its portfolio company
Thrombotech. According to Dr. Rafi Hofstein, CEO of Hadasit Bio-Holdings, “the investment in Thrombotech is an expression of our
faith in the company’s success during recent months in developing a treatment for stroke. Thrombotech has managed to demonstrate
that it has a solution that can provide excellent treatment for the severe side-effects of the drugs currently in use. Most of the drugs
administered today, especially those developed by Genentech (tPA), are effective, but in order to make sure that the patient is not
exposed to the side-effects, characterized mainly by internal hemorrhage, there is a narrow window for treatment, estimated at about
three hours after the onset of the stroke.
On the basis of the trials and findings in an animal model, the drug being developed by
Thrombotech can be expected to
show similar effectiveness, but the window for administration will be longer, up to nine hours after the
event.”
http://www.hbl.co.il/press_item.asp?ID=8
Thrombotech Ltd., A Portfolio Company Of Hadasit Bio-Holdings Ltd., Reports New Findings At The Conclusion Of Animal
Trials
May. 9, 2006
Tel Aviv, Israel, May 9, 2006. Hadasit Bio-Holdings Ltd. (TASE symbol: HDST) announced today that Thrombotech Ltd., one of its
portfolio companies, has concluded laboratory trials demonstrating that a peptide developed by the company, administered in
combination with existing drugs for the treatment of strokes or acute myocardial infarction (tPA, manufactured by Genentech), seems to
prevent the side effects and hemorrhage and significantly reduces the intracerebral hemorrhage that accompanies the drugs in use
today. It was also found that this peptide may reduce the size of necroses caused by the administration of the existing drugs by up to
threefold.
http://www.hbl.co.il/press_item.asp?ID=5 |
